Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Enhance your knowledge of approved and investigational antibody–drug conjugates targeting HER2, HER3, TROP2, or B7-H3 in lung cancer, including the differences in ADC characteristics, the latest efficacy and safety data, and strategies for optimal patient selection, through an on-demand webcast with accompanying slides and a ClinicalThought commentary.

Share

Program Content

Activities

ADCs in EGFR-Mutated NSCLC
Antibody–Drug Conjugates in EGFR-Mutated NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

ADCs in HER2-Mutated NSCLC
ADCs in HER2-Mutated NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

TROP 2 ADCs and ADCs in SCLC
Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: September 16, 2024

Expires: September 15, 2025

Faculty

cover img faculity

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Villejuif, France

cover img faculity

Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine
Department of Pulmonary Diseases
Leiden University Medical Center
Leiden, Netherlands

cover img faculity

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.